1. Home
  2. BLFY vs IPHA Comparison

BLFY vs IPHA Comparison

Compare BLFY & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLFY
  • IPHA
  • Stock Information
  • Founded
  • BLFY 1939
  • IPHA 1999
  • Country
  • BLFY United States
  • IPHA France
  • Employees
  • BLFY N/A
  • IPHA N/A
  • Industry
  • BLFY Commercial Banks
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLFY Finance
  • IPHA Health Care
  • Exchange
  • BLFY Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • BLFY 196.6M
  • IPHA 160.1M
  • IPO Year
  • BLFY N/A
  • IPHA 2019
  • Fundamental
  • Price
  • BLFY $8.50
  • IPHA $2.11
  • Analyst Decision
  • BLFY Hold
  • IPHA Strong Buy
  • Analyst Count
  • BLFY 1
  • IPHA 1
  • Target Price
  • BLFY $10.00
  • IPHA $11.00
  • AVG Volume (30 Days)
  • BLFY 50.0K
  • IPHA 13.4K
  • Earning Date
  • BLFY 07-30-2025
  • IPHA 09-11-2025
  • Dividend Yield
  • BLFY N/A
  • IPHA N/A
  • EPS Growth
  • BLFY N/A
  • IPHA N/A
  • EPS
  • BLFY N/A
  • IPHA N/A
  • Revenue
  • BLFY $41,939,000.00
  • IPHA $20,831,349.00
  • Revenue This Year
  • BLFY $20.14
  • IPHA $278.51
  • Revenue Next Year
  • BLFY $20.20
  • IPHA $70.16
  • P/E Ratio
  • BLFY N/A
  • IPHA N/A
  • Revenue Growth
  • BLFY 0.22
  • IPHA N/A
  • 52 Week Low
  • BLFY $8.24
  • IPHA $1.29
  • 52 Week High
  • BLFY $11.38
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • BLFY 32.54
  • IPHA 60.15
  • Support Level
  • BLFY $8.24
  • IPHA $1.71
  • Resistance Level
  • BLFY $9.26
  • IPHA $2.63
  • Average True Range (ATR)
  • BLFY 0.25
  • IPHA 0.14
  • MACD
  • BLFY -0.08
  • IPHA 0.03
  • Stochastic Oscillator
  • BLFY 23.04
  • IPHA 41.83

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: